Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1637 1672 1682 1683
This examiner grants 29% of resolved cases
Kailey Elizabeth Cash is an examiner in Art Unit 1637 of Tech Center 1600. She has a total of 21 resolved cases in her profile. The allowance rate for these cases is 28.6%, which indicates a very challenging environment for securing a patent grant. This 28.6% rate suggests that a large majority of applications do not reach allowance. Practitioners should be prepared for a difficult prosecution path when their cases are assigned to this unit.
The data highlights a very high interview lift of 64.3%. This figure represents the increase in the probability of allowance following an interview compared to the baseline allowance rate of 28.6%. This 64.3% lift suggests that direct verbal communication with the examiner is an extremely effective strategy. Engaging in an interview may be the most critical step an applicant can take to improve their chances of success.
The median days to allowance for successful applications is 1351. This 1351-day figure provides a benchmark for the expected duration of the prosecution cycle. Given the 21 resolved cases and the 28.6% allowance rate, practitioners should anticipate a lengthy and difficult process. The 1351-day median and the 64.3% interview lift should be central factors in any prosecution plan for Art Unit 1637.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18557631 | HIGH THROUGHPUT NUCLEIC ACID TESTING OF BIOLOGICAL SAMPLES | Non-Final OA | ABBOTT LABORATORIES |
| 17687376 | SYSTEMS AND METHODS FOR BARCODING CELLS AND CELL BEADS | Non-Final OA | 10x Genomics, Inc. |
| 17768996 | CLINICAL- AND INDUSTRIAL-SCALE INTACT-TISSUE SEQUENCING | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18264741 | A CONTINUOUS METRIC TO MEASURE ENDOTYPE AND CORTICOSTEROID INTERACTION IN SEPTIC SHOCK | Final Rejection | VANDERBILT UNIVERSITY |
| 18157587 | Methods Of Improving Health With Apolipoprotein E (APOE) Inhibitors | Non-Final OA | Regeneron Pharmaceuticals, Inc. |
| 18468384 | PANELS AND METHODS FOR TREATMENT OF DIFFUSE LARGE B-CELL LYMPHOMA | Non-Final OA | The General Hospital Corporation |
| 18000222 | SINGLE CELL COMBINATORIAL INDEXING FROM AMPLIFIED NUCLEIC ACIDS | Final Rejection | THE GENERAL HOSPITAL CORPORATION |
| 17999960 | NON-EXTENSIBLE OLIGONUCLEOTIDES IN DNA AMPLIFICATION REACTIONS | Non-Final OA | William Marsh Rice University |
| 18706126 | KITS AND METHODS FOR QUANTITATIVE ASSESSMENT AND ENRICHMENT OF EXTRACHROMOSOMAL CIRCULAR DNA | Non-Final OA | CEDARS-SINAI MEDICAL CENTER |
| 17642640 | DETECTION OF CIRCULATING TUMOR DNA USING DOUBLE STRANDED HYBRID CAPTURE | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 18372576 | CULTURE-FREE BIPHASIC APPROACH FOR RAPID DETECTION OF PATHOGENS FROM WHOLE BLOOD | Non-Final OA | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS |
| 18203189 | Quantum Dot-Peptide PNA-DNA Complexes as a Platform Reporter System for Multiplexed Detection in Cell-Free Transcription Translation-Based Biosensors | Non-Final OA | The Government of the United States of America, as represented by the Secretary of the Navy |
| 18578997 | MODIFIED ADAPTERS FOR ENZYMATIC DNA DEAMINATION AND METHODS OF USE THEREOF FOR EPIGENETIC SEQUENCING OF FREE AND IMMOBILIZED DNA | Non-Final OA | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA |
| 18709782 | FRAGMENT CONSENSUS METHODS FOR ULTRASENSITIVE DETECTION OF ABERRANT METHYLATION | Non-Final OA | Foundation Medicine, Inc. |
| 18577860 | A METHOD FOR DETECTION OF TARGET NUCLEIC ACID USING ISOTHERMAL AMPLIFICATION | Non-Final OA | Agency for Science, Technology and Research |
| 17744231 | METHODS FOR DISEASE DETECTION | Non-Final OA | Universal Diagnostics, S.A. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy